▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2195 by analyst upside · 2026-09-27
ZLAB
Zai Lab Limited
Healthcare · Market Cap $3B · P/E 0x
ANALYST PRICE TARGET
+32.7%
implied upside to consensus target
Current Price $24.98
Consensus Target $33.14
Bull Target $50.0
Bear Target $24.25
Analysts Covering 12
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
9
Hold
1
Sell
0
52-Week Low $15.96
52-Week High $34.72
YTD Return +44.1%
FUNDAMENTALS
Market Cap $3B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.70
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $450M
Profit Margin -41.9%
52-WEEK RANGE
52-Week Low $15.96
52-Week High $34.72
Current Price $24.98
Bear Target $24.25
Bull Target $50.0
● Now $24.98 ● Target $33.14
TRADING DATA
Avg Volume 958K
YTD Return +44.1%
Analyst Count 12
Consensus Buy
Upside to Target +32.7%
Last Updated 2026-09-27

ANALYST SUMMARY

Zai Lab Limited (ZLAB) is currently trading at $24.98 with a Wall Street consensus price target of $33.14, implying potential upside of 32.7% over the next 12 months. 12 analysts currently cover ZLAB, with a consensus rating of Buy - 92% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $50.0, while the most cautious has a target of $24.25.

ZLAB operates in the Healthcare sector with a market capitalisation of $3B. The stock is up 44.1% year-to-date and is currently trading near the lower end of its 52-week range of $15.96 – $34.72.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ZLAB, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citigroup - Reiterated
Buy → Buy 2026-08-07 Building track record
Citigroup - Reiterated
Buy → Buy 2026-05-08 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-03-18 43% win rate (7 calls)
Cantor Fitzgerald - Reiterated
Overweight → Overweight 2026-02-27 40% win rate (10 calls)
JP Morgan - Reiterated
Overweight → Overweight 2026-02-05 43% win rate (7 calls)
UBS ● Initiated
Buy 2026-01-07 33% win rate (6 calls)
Citigroup - Reiterated
Buy → Buy 2025-08-11 Building track record
Leerink Partners - Reiterated
Outperform → Outperform 2025-06-30 29% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
51
out of 100
Coverage depth
20/30
Consensus clarity
9/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →